Literature DB >> 8541108

Survival in interval breast cancer in the DOM screening programme.

C T Brekelmans1, P H Peeters, J J Deurenberg, H J Collette.   

Abstract

The study describes breast cancer survival of 75 interval cancer cases (cancer occurring within 2 years of a negative screen) detected in women who participated in the DOM screening programme. After mammographic revision, this group was divided into 17 so-called 'missed' cases and 58 'true' interval cases. Ten year survival of these 58 'true' interval cases was 58%, which was not significantly different from that of 219 cancers detected in a non-screened, control group of women, diagnosed with breast cancer before the start of screening (63%; log rank chi 2 test, P = 0.98). Results remained essentially the same after correction for age at diagnosis, tumour size, axillary status and year of diagnosis. Ten year survival of 'true' interval cancers (58%) was slightly worse than that of 'missed' cases (67%; log rank chi 2 test: P = 0.38). This difference could largely be explained by differences in tumour size and axillary status. We conclude that there was no important difference in survival between 'true' interval cancers and non-screened historical controls. This could mean that either this subgroup of interval cancers does not constitute an excess of rapidly growing tumours, or if it does, that a fast growth rate is not associated with an exceptionally poor prognosis.

Entities:  

Mesh:

Year:  1995        PMID: 8541108     DOI: 10.1016/0959-8049(95)00324-c

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

1.  Differences between screen-detected and interval breast cancers among BRCA mutation carriers.

Authors:  Melissa Pilewskie; Emily C Zabor; Elizabeth Gilbert; Michelle Stempel; Oriana Petruolo; Debra Mangino; Mark Robson; Maxine S Jochelson
Journal:  Breast Cancer Res Treat       Date:  2019-01-23       Impact factor: 4.872

2.  Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).

Authors:  Cheryl Lin; Meredith Becker Buxton; Dan Moore; Helen Krontiras; Lisa Carey; Angela DeMichele; Leslie Montgomery; Debasish Tripathy; Constance Lehman; Minetta Liu; Olufunmilayo Olapade; Christina Yau; Donald Berry; Laura J Esserman
Journal:  Breast Cancer Res Treat       Date:  2011-07-28       Impact factor: 4.872

3.  A study of interval breast cancer within the NHS breast screening programme.

Authors:  W K Cowan; B Angus; J C Gray; L G Lunt; S R al-Tamimi
Journal:  J Clin Pathol       Date:  2000-02       Impact factor: 3.411

4.  Could screening participation bias symptom interpretation? An interview study on women's interpretations of and responses to cancer symptoms between mammography screening rounds.

Authors:  Marit Solbjør; John-Arne Skolbekken; Ann Rudinow Sætnan; Anne Irene Hagen; Siri Forsmo
Journal:  BMJ Open       Date:  2012-11-12       Impact factor: 2.692

5.  Prognosis in women with interval breast cancer: population based observational cohort study.

Authors:  Mette Kalager; Rulla M Tamimi; Michael Bretthauer; Hans-Olov Adami
Journal:  BMJ       Date:  2012-11-16

6.  Role of mammography screening as a predictor of survival in postmenopausal breast cancer patients.

Authors:  J Anttinen; H Kautiainen; T Kuopio
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640

7.  Survival analysis of patients with interval cancer undergoing gastric cancer screening by endoscopy.

Authors:  Chisato Hamashima; Michiko Shabana; Mikizo Okamoto; Yoneatsu Osaki; Takuji Kishimoto
Journal:  PLoS One       Date:  2015-05-29       Impact factor: 3.240

8.  Are international differences in breast cancer survival between Australia and the UK present amongst both screen-detected women and non-screen-detected women? survival estimates for women diagnosed in West Midlands and New South Wales 1997-2006.

Authors:  Laura M Woods; Bernard Rachet; Dianne L O'Connell; Gill Lawrence; Michel P Coleman
Journal:  Int J Cancer       Date:  2016-02-23       Impact factor: 7.396

9.  Aggressive primary treatments with favourable 5-year survival for screen-interval breast cancers.

Authors:  Gautier Defossez; Alexandre Quillet; Pierre Ingrand
Journal:  BMC Cancer       Date:  2018-04-06       Impact factor: 4.430

10.  Detection methods predict differences in biology and survival in breast cancer patients.

Authors:  Maximino Redondo; Rafael Funez; Francisco Medina-Cano; Isabel Rodrigo; Mercedes Acebal; Teresa Tellez; M Jose Roldan; M Luisa Hortas; Ana Bellinvia; Teresa Pereda; Laia Domingo; María Morales-Suarez Varela; Maria Sala; Antonio Rueda
Journal:  BMC Cancer       Date:  2012-12-17       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.